Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure Substudy of the RE-LY trial

Publication Date

2015

Journal Title

Thromb Haemost

Abstract

In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain. We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for stroke prevention in AF, to assess the potential benefits and risks of bridging. In patients who had a first interruption of dabigatran or warfarin for an elective surgery/procedure, we compared the risk for major bleeding (MB), stroke or systemic embolism (SSE) and any thromboembolism (TE) in patients who were bridged or not bridged during the period of seven days before until 30 days after surgery/procedure. We used multivariable Cox regression to adjust for potential confounders. Bridging was used more during warfarin interruption than dabigatran interruption (27.5% vs 15.4%; p

Volume Number

113

Issue Number

3

Pages

625-632

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

General Internal Medicine

PMID

25472710

DOI

10.1160/th14-04-0305

Comments

Hofstra Northwell School of Medicine and Northwell Health currently do not subscribe to this title. If you are an affiliate and would like to access the full text please request it via interlibrary loan via Hofstra Northwell School of Medicine ILL (faculty and students only) or Northwell Health ILL

This document is currently not available here.


Share

COinS